GPT (also known as Alanine Aminotransferase or ALT) is a pyridoxal phosphate-dependent aminotransferase enzyme primarily expressed in the liver, with lower expression in kidney, heart, skeletal muscle, and brain tissue[1]. While classically considered a clinical marker for liver injury, emerging research has revealed important functions for ALT in systemic metabolism and its dysregulation in neurodegenerative diseases through the liver-brain axis[2].
| GPT — Alanine Transaminase | |
|---|---|
| Gene Symbol | GPT |
| Full Name | Alanine Aminotransferase |
| Chromosome | 8q24.3 |
| NCBI Gene ID | [2595](https://www.ncbi.nlm.nih.gov/gene/2595) |
| OMIM | 613208 |
| Ensembl ID | ENSG00000149806 |
| UniProt ID | [P24259](https://www.uniprot.org/uniprot/P24259) |
| Associated Diseases | [Liver Disease](/diseases/fatty-liver-disease), [Metabolic Syndrome](/mechanisms/metabolic-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
The GPT gene is located on chromosome 8q24.3 and encodes a protein of approximately 496 amino acids. GPT exists as a homodimer, with each monomer containing a pyridoxal phosphate (PLP) cofactor bound at an active site lysine residue[1:1]. The enzyme catalyzes the reversible transamination between alanine and α-ketoglutarate, producing pyruvate and glutamate:
Alanine + α-Ketoglutarate ↔ Pyruvate + Glutamate
This reaction is central to the alanine-glucose cycle (Cahill cycle), which links hepatic gluconeogenesis with peripheral tissue metabolism.
| Property | Value |
|---|---|
| EC Number | 2.6.1.2 |
| Cofactor | Pyridoxal phosphate (PLP) |
| Substrate | L-alanine + α-ketoglutarate |
| Product | Pyruvate + L-glutamate |
| Tissue Distribution | Liver > Kidney > Heart >> Brain |
| Molecular Weight | ~55 kDa per subunit |
Two ALT isoforms have been identified:
Both isoforms are present in the brain, with differential expression across brain regions. ALT2 (mitochondrial) is particularly relevant to neuronal energy metabolism.
GPT plays several essential metabolic roles[1:2]:
Amino Acid Metabolism: ALT catalyzes the reversible transfer of amino groups between alanine and α-ketoglutarate, contributing to nitrogen metabolism and the urea cycle[3:1].
Gluconeogenesis: During fasting, ALT facilitates hepatic gluconeogenesis by converting alanine-derived carbon to glucose. This is critical for maintaining blood glucose levels during prolonged fasting.
Alanine-Glucose Cycle (Cahill Cycle): ALT is a key enzyme in this cycle:
Intermediary Metabolism: ALT connects carbohydrate and amino acid metabolism, allowing cells to adapt to changing energy demands.
Nitrogen Metabolism: Part of hepatic nitrogen disposal and detoxification.
In neurons, ALT (particularly the mitochondrial ALT2 isoform) contributes to:
In the brain, GPT is expressed at low levels in:
Brain GPT may serve local nitrogen metabolism and neurotransmitter precursor synthesis.
The liver-brain axis represents a critical bidirectional communication pathway whereby hepatic dysfunction can influence brain function and vice versa[2:1]. ALT serves as both a marker and potential mediator of this axis in neurodegeneration.
Circulating Metabolites: The liver produces hepatokines (liver-derived signaling proteins) that affect brain function. Liver dysfunction alters the secretome, impacting neuronal survival[4].
Inflammatory Mediators: Liver disease increases circulating pro-inflammatory cytokines (IL-6, TNF-α) that can cross the blood-brain barrier and trigger neuroinflammation[5].
Ammonia Detoxification: The liver detoxifies ammonia via the urea cycle. Impaired liver function leads to hyperammonemia, which is neurotoxic and can contribute to hepatic encephalopathy[2:2].
Xenobiotic Metabolism: The liver clears circulating toxins and metabolites. Impaired clearance allows potentially neurotoxic compounds to accumulate[6].
Autophagy: The liver plays a key role in systemic autophagy. Liver dysfunction can impair clearance of misfolded proteins systemically, potentially affecting brain protein clearance[2:3].
Multiple studies have linked ALT dysregulation to Alzheimer's disease pathogenesis[7][8]:
Metabolic Syndrome: Elevated ALT is associated with metabolic syndrome, a known risk factor for AD. Insulin resistance and dyslipidemia contribute to amyloidogenesis and tau pathology[5:1][9].
Amyloid-β Metabolism: The liver produces apolipoproteins that influence Aβ clearance. Liver dysfunction can impair this clearance mechanism[6:1].
Tau Pathology: ALT elevation correlates with tau pathology in some studies, possibly reflecting shared metabolic dysfunction[10].
Cognitive Decline: Cohort studies have shown that elevated ALT in midlife is associated with faster cognitive decline and increased AD risk[11][12].
The relationship between ALT and Parkinson's disease involves multiple pathways[13][14]:
Metabolic Factors: ALT elevation is associated with altered PD risk in some cohorts, possibly reflecting compensation for altered metabolism.
Gut-Liver-Brain Axis: Liver dysfunction may contribute to PD through altered xenobiotic metabolism and increased intestinal permeability[15].
Mitochondrial Function: ALT2 is mitochondrially localized, and its dysregulation may affect neuronal energy metabolism[16].
ALT and other liver enzymes are often abnormal in Huntington's disease[17]:
Metabolic Dysfunction: Elevated ALT correlates with disease progression and may reflect hepatic involvement or altered energy metabolism.
Systemic Changes: HD patients show metabolic abnormalities including altered gluconeogenesis and muscle wasting, with ALT reflecting these systemic changes.
| Disease | Association | Mechanism |
|---|---|---|
| Non-Alcoholic Fatty Liver Disease (NAFLD) | Elevated ALT | Hepatic steatosis, inflammation |
| Metabolic Syndrome | Elevated ALT | Insulin resistance, adiposity |
| Alzheimer's Disease | Mixed associations | Liver-brain axis, metabolism |
| Parkinson's Disease | Mixed associations | Metabolic compensation, gut-liver axis |
| Huntington's Disease | Elevated ALT | Systemic metabolic dysfunction |
GPT is a key clinical marker for:
Elevated ALT is strongly associated with:
Elevated GPT reflects hepatic inflammation that can affect the brain:
The liver's role in systemic autophagy links to neurodegeneration:
GPT elevation often accompanies dyslipidemia:
The GPT-metabolic syndrome connection affects brain energy:
ALT is primarily used as a clinical marker for liver injury:
In the context of neurodegeneration, ALT serves as an indirect marker of:
Understanding ALT's role in the liver-brain axis suggests potential therapeutic approaches[5:3]:
Metabolic Modulation: Improving insulin sensitivity and reducing metabolic syndrome may benefit both liver and brain.
Anti-inflammatory Therapy: Reducing systemic inflammation could protect against liver-mediated neuroinflammation.
Hepatoprotective Agents: Protecting liver function may help maintain the liver-brain axis.
Lifestyle Interventions: Diet and exercise can lower ALT and improve brain health.
In the brain, GPT supports neuronal metabolism:
Alanine aminotransferase. 2006. ↩︎ ↩︎ ↩︎
Metabolic impairment in neurodegenerative disease. 2011. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hepatokines and brain function. 2011. ↩︎
Metabolic syndrome and cognitive impairment. 2009. ↩︎ ↩︎ ↩︎ ↩︎
Liver dysfunction and Alzheimer's disease biomarkers. 2015. ↩︎ ↩︎
Serum ALT and Alzheimer's disease systematic review. 2022. ↩︎
ALT and tau pathology in AD. 2018. ↩︎